PROTECT and NefIgArd 2-Year Proteinuria and eGFR Outcomes in Adults with IgA Nephropathy: Matching-Adjusted Indirect Comparison (MAIC)

Matching-Adjusted Indirect Comparisons of eGFR Slopes in the PROTECT study with UK RaDaR IgA Nephropathy Population and the Control Arm of NefIgArd

Sparsentan vs Irbesartan in Patients With Immunoglobulin A Nephropathy (IgAN): Subgroup Analyses of 2-Year Results From the Pivotal Phase 3 PROTECT Trial Presentation

Effects of Proteinuria Reduction on Delay of Kidney Failure in Patients With Immunoglobulin A Nephropathy

Preliminary Findings From the Phase 2 EPPIK Study of Sparsentan in Pediatric Patients With Selected Proteinuric Glomerular Diseases

Sparsentan vs Irbesartan in Patients With Focal Segmental Glomerulosclerosis (FSGS): Results From the Phase 3 DUPLEX Trial

Rate of Loss of eGFR and Time-Averaged Proteinuria in IgAN Patients Progressing From​ Early Stage Disease to Kidney Failure 

Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)

Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in the PROTECT Open-Label Extension (OLE) Substudy and SPARTACUS: Trials in Progress

Proteinuria and kidney survival in focal segmental​ glomerulosclerosis (FSGS) or immunoglobulin A nephropathy​ (IgAN): A NEPTUNE analysis

Predictors of Major Adverse Kidney Disease Events in a Real-World Population With IgA Nephropathy

The Humanistic Burden of Rare Kidney Diseases: Understanding the Impact of Focal Segmental Glomerulosclerosis (FSGS) and Immunoglobulin A Nephropathy (IgAN) on Patients and Caregivers Study (HONUS): Results for FSGS in the United States (US)